Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 519,359 | 449,810 | 408,742 | 501,693 | 486,030 |
| Cost of Goods | 116,965 | 119,750 | 103,537 | 127,062 | 120,166 |
| Gross Profit | 402,394 | 330,060 | 305,205 | 374,631 | 365,864 |
| Operating Expenses | 266,032 | 396,690 | 358,961 | 363,021 | 340,944 |
| Operating Income | 137,327 | -65,880 | -53,219 | 11,672 | 25,086 |
| Interest Expense | 3,806 | 3,846 | 3,870 | 3,817 | 3,804 |
| Other Income | 666 | 3,152 | 10,929 | 6,301 | 1,946 |
| Pre-tax Income | 134,187 | -66,574 | -46,160 | 14,156 | 23,228 |
| Income Tax | 13,389 | -8,676 | -9,666 | 1,215 | 5,857 |
| Net Income Continuous | 120,798 | -57,898 | -36,494 | 12,941 | 17,371 |
| Net Income | $120,798 | $-57,898 | $-36,494 | $12,941 | $17,371 |
| EPS Basic Total Ops | 0.66 | -0.32 | -0.20 | 0.07 | 0.10 |
| EPS Basic Continuous Ops | 0.66 | -0.32 | -0.20 | 0.07 | 0.10 |
| EPS Diluted Total Ops | 0.63 | -0.31 | -0.20 | 0.07 | 0.09 |
| EPS Diluted Continuous Ops | 0.62 | -0.32 | -0.20 | 0.07 | 0.09 |
| EBITDA(a) | $166,322 | $-38,018 | $-24,979 | $40,108 | $53,742 |